This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Assertio Therapeutics (ASRT) to Post Q1 Earnings: What's Up?
by Zacks Equity Research
During Assertio Therapeutics' (ASRT) Q1 conference call, investor focus will be on the company's progress with its neurology franchise and the NDA filing for cosyntropin.
Collegium Pharmaceutical (COLL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical (COLL) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Collegium Pharmaceutical (COLL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Collegium Pharmaceutical (COLL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ASRT or COLL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ASRT vs. COLL: Which Stock Is the Better Value Option?
ASRT vs. COLL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. COLL: Which Stock Is the Better Value Option?
ASRT vs. COLL: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
ASRT vs. COLL: Which Stock Is the Better Value Option?
Collegium Pharmaceutical (COLL) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -127.27% and -6.94%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Collegium Pharmaceutical (COLL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Collegium Pharmaceutical (COLL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Collegium Pharmaceutical (COLL) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of 65.91% and 4.06%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Nektar (NKTR) Seeks Approval for Analgesic Opioid Candidate
by Zacks Equity Research
Nektar (NKTR) submits NDA to the FDA seeking approval of its analgesic opioid candidate, NKTR-181, for the treatment of chronic low back pain.
What's in Store for Penumbra (PEN) This Earnings Season?
by Zacks Equity Research
Penumbra (PEN) deepens its focus on driving innovation, ramping up production and expanding geographies.
Collegium Pharmaceutical, Inc. (COLL) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Collegium Pharmaceutical, Inc. (COLL) Sees Hammer Chart Pattern: Time to Buy?
Sage Therapeutics Soars: Stock Adds 7.1% in Session
by Zacks Equity Research
Sage Therapeutics (SAGE) was a big mover last session, as the company saw its shares rise more than 7% on the day.
Valeant (VRX) in Focus: Stock Moves 11.7% Higher
by Zacks Equity Research
Valeant Pharmaceuticals International (VRX) was a big mover last session, as the company saw its shares rise nearly 12% on the day.
Top Ranked Momentum Stocks to Buy for November 27th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 27th:
Top Ranked Momentum Stocks to Buy for November 22nd
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 22nd:
Collegium (COLL) in Focus: Stock Moves 6.9% Higher
by Zacks Equity Research
Collegium Pharmaceutical (COLL) was a big mover last session, as the company saw its shares rise nearly 7% on the day amid huge volumes.
Top Ranked Momentum Stocks to Buy for November 16th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 16th:
Top Ranked Momentum Stocks to Buy for November 14th
by Zacks Equity Research
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, November 14th:
Collegium Pharmaceutical (COLL) Looks Good: Stock Adds 6% in Session
by Zacks Equity Research
Collegium Pharmaceutical (COLL) shares rose 6% in the last trading session, amid huge volumes.
BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End
by Zacks Equity Research
BioDelivery Sciences (BDSI) President and CEO, Mark Sirgo, is set to retire this year.
BioDelivery (BDSI) Q2 Loss Wider than Expected, Stock Falls
by Zacks Equity Research
BioDelivery Sciences International (BDSI) reported wider-than-expected Q2 loss. However, Belbuca registered record sales for the second consecutive quarter.
Nektar's NKTR-181 Positive in Human Abuse Potential Study
by Zacks Equity Research
Positive top line results from an oral human abuse potential (HAP) study, evaluating the opioid analgesic candidate -- NKTR-181 -- to assess abuse potential compared with oxycodone, nudged up Nektar's (NKTR) shares.
Nektar's Pain Drug Positive in Phase III Study; Shares Gain
by Zacks Equity Research
Nektar Therapeutics??? (NKTR) shares surged 42.6% after the company announced positive results from a phase III efficacy study evaluating its investigational candidate, NKTR-181, in patients with moderate to severe chronic low back pain.